|
Video: What is a Stock Split?
|
|
DelMar Pharmaceuticals is a clinical stage, biopharmaceutical company. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and other solid tumors, including ovarian cancer and non-small cell lung cancer. Co. is also conducting open-label, biomarker driven studies in methyl guanine methyltransferase-unmethylated GBM. In addition to its clinical development activities in the United States, Co. has provided Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer. According to our DMPI split history records, DMPI has had 1 split. | |
|
DMPI (DMPI) has 1 split in our DMPI split history database. The split for DMPI took place on May 08, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of DMPI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as DMPI conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the DMPI split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into DMPI shares, starting with a $10,000 purchase of DMPI, presented on a split-history-adjusted basis factoring in the complete DMPI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
08/19/2020 |
|
Start price/share: |
$11.70 |
|
End price/share: |
$1.34 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-88.55% |
|
Average Annual Total Return: |
-28.98% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,145.55 |
|
Years: |
6.33 |
|
|
|
Date |
Ratio |
05/08/2019 | 1 for 10 |
|
|